蛋白质二硫化异构酶可以溶解和排毒粉样β的寡合组合
Antonio Mele1, Albert Serrano1, Maria C Zabala-Rodriguez1
1Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA.
FEBS letters
|February 20, 2026
概括
蛋白二硫化异构酶 (PDI) 溶解有毒的粉样蛋白β (Aβ) 寡合体,提供抗阿尔茨海默病的神经保护. 这种分解活性针对的是早期的Aβ聚合物,而不是纤维,这表明了治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默氏病 (AD) 与聚合的粉样β (Aβ) 有关,它们表现出神经毒性和类似的传播.
- 了解Aβ聚合和清除的机制对于开发AD疗法至关重要.
研究的目的:
- 调查蛋白质二硫化异构酶 (PDI) 对不同形式的粉样β (Aβ) 的分解活性.
- 通过检查其与Aβ寡合体的相互作用及其对细胞毒性的影响来确定PDI作为阿尔茨海默病治疗剂的潜力.
主要方法:
- 评估PDI对Aβ. monomeric,oligomeric和纤维状形式的分解活性.
- 评估PDI与各种Aβ物种的结合亲和力.
- 在细胞模型中测试PDI对Aβ诱导毒性的神经保护作用.
- 调查S-化PDI对Aβ结合和分解活性的影响.
主要成果:
- PDI对寡合体Aβ但非纤维状Aβ显示出显著的分解活性.
- PDI没有结合单体Aβ,表明其机制涉及逆转早期寡合体.
- 用PDI和寡合性Aβ治疗的细胞被保护免受Aβ诱导的神经毒性.
- 与神经退行相关的S-基化PDI失去了结合寡合体Aβ的能力及其神经保护性分解酶活性.
结论:
- PDI具有分聚活性,特别针对Aβ的神经毒性寡合形式.
- PDI与Aβ寡合体的相互作用为阿尔茨海默病提供了潜在的治疗策略.
- 调节PDI活动,特别是避免S-化,可能是其神经保护作用的关键.
相关概念视频
Protein and Protein Structure
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme can...
A protein's shape is critical to its function. For example, an enzyme can...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Protein Modifications in the RER
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
Protein Folding
Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...


